Is it safe to prescribe clomiphene citrate without ultrasound monitoring facilities?
dc.contributor.author | Coughlan, C | |
dc.contributor.author | Fitzgerald, J | |
dc.contributor.author | Milne, P | |
dc.contributor.author | Wingfield, M | |
dc.date.accessioned | 2012-03-30T14:01:00Z | |
dc.date.available | 2012-03-30T14:01:00Z | |
dc.date.issued | 2010-05 | |
dc.identifier.citation | Is it safe to prescribe clomiphene citrate without ultrasound monitoring facilities? 2010, 30 (4):393-6 J Obstet Gynaecol | |
dc.identifier.issn | 1364-6893 | |
dc.identifier.pmid | 20455725 | |
dc.identifier.doi | 10.3109/01443611003646280 | |
dc.identifier.uri | http://hdl.handle.net/10147/217195 | |
dc.description.abstract | The majority of triplet and higher order multiple pregnancies now result from ovulation induction/superovulation rather than in vitro fertilisation. However, clomiphene citrate is still widely prescribed by gynaecologists and general practitioners who do not have access to ultrasound monitoring. The objective of our study was to determine the prevalence of multifollicular development with different doses of clomiphene citrate. A retrospective review of transvaginal ultrasound monitoring of 425 cycles in 182 women receiving clomiphene citrate from January 2002 to December 2003, was studied. Three or more follicles of >or= 14 mm were identified in 58 cycles (14%). Patients received 50 mg of clomiphene citrate in 52 of these 58 cycles and 25 mg in the remaining six. One patient was noted to have developed five follicles and 10 patients developed four follicles. One patient developed six follicles, despite receiving only 25 mg clomiphene citrate daily. It was concluded that a significant number of women (14%) developed three or more follicles, despite receiving low doses of clomiphene citrate. | |
dc.language.iso | en | |
dc.rights | Archived with thanks to Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology | en_GB |
dc.subject.mesh | Clomiphene | |
dc.subject.mesh | Female | |
dc.subject.mesh | Fertility Agents, Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Pregnancy | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Superovulation | |
dc.subject.mesh | Ultrasonography | |
dc.title | Is it safe to prescribe clomiphene citrate without ultrasound monitoring facilities? | en_GB |
dc.contributor.department | Merrion Fertility Clinic, National Maternity Hospital, Dublin, Republic of Ireland. C.J.Coughlan@sheffield.ac.uk | |
dc.identifier.journal | Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology | |
dc.type.qualificationlevel | N/A | en |
cr.approval.ethical | N/A | en |
dc.description.province | Leinster | en |
dc.description.province | Leinster | |
html.description.abstract | The majority of triplet and higher order multiple pregnancies now result from ovulation induction/superovulation rather than in vitro fertilisation. However, clomiphene citrate is still widely prescribed by gynaecologists and general practitioners who do not have access to ultrasound monitoring. The objective of our study was to determine the prevalence of multifollicular development with different doses of clomiphene citrate. A retrospective review of transvaginal ultrasound monitoring of 425 cycles in 182 women receiving clomiphene citrate from January 2002 to December 2003, was studied. Three or more follicles of >or= 14 mm were identified in 58 cycles (14%). Patients received 50 mg of clomiphene citrate in 52 of these 58 cycles and 25 mg in the remaining six. One patient was noted to have developed five follicles and 10 patients developed four follicles. One patient developed six follicles, despite receiving only 25 mg clomiphene citrate daily. It was concluded that a significant number of women (14%) developed three or more follicles, despite receiving low doses of clomiphene citrate. |